Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016-2018.

In this report, omadacycline and comparators were tested against 49,000 non-duplicate bacterial isolates collected prospectively during 2016-2018 from medical centers in Europe (24,500 isolates; 40 medical centers [19 countries]) and the United States (24,500 isolates; 33 medical centers [23 states and all 9 United States Census Divisions]). Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07 (2018) methods.Omadacycline (MIC50/90, 0.12/0.25 mg/L) inhibited 98.6% of Staphylococcus aureus isolates at ≤0.5 mg/L including 96.3% of methicillin-resistant S. aureus and 99.8% of methicillin-susceptible S. aureus Omadacycline potency was comparable for Streptococcus pneumoniae (MIC50/90, 0.06/0.12 mg/L), viridans group streptococci (MIC50/90, 0.06/0.12 mg/L) and β-hemolytic streptococci (MIC50/90, 0.12/0.25 mg/L) regardless of species and susceptibility to penicillin, macrolides or tetracycline. Omadacycline was active against Enterobacterales (MIC50/90, 1/8 mg/L; 87.5% inhibited at ≤4 mg/L) except Proteus mirabilis (MIC50/90, 16/>32 mg/L) and Indole-positive Proteus spp. (MIC50/90, 8/32 mg/L) and was most active against Escherichia coli (MIC50/90, 0.5/2 mg/L), Klebsiella oxytoca (MIC50/90, 1/2 mg/L) and Citrobacter spp. (MIC50/90, 1/4 mg/L). Omadacycline inhibited 92.4% of Enterobacter cloacae species complex and 88.5% of Klebsiella pneumoniae isolates at ≤4 mg/L. Omadacycline was active against Haemophilus influenzae (MI...

Source: Antimicrobial Agents and Chemotherapy - February 17, 2020 Category: Microbiology Authors: Pfaller MA, Huband MD, Shortridge D, Flamm RK Tags: Antimicrob Agents Chemother Source Type: research